gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLCgastro-j-1000Research ArticleГЕПАТОЛОГИЯHEPATOLOGYНеинвазивная диагностика фиброза печени: роль сывороточных маркёровNon-invasive of liver fibrosis diagnostics: the role of serum markersШептулинаА. Ф.SheptulinaA. F.

Шептулина Анна Фароковна — аспирант кафедры пропедевтики внутренних болезней

119991, Москва, ул. Погодинская, д. 1, стр. 1. 

Sheptulina Anna F. – PhD student of the Chair of internal diseases propedeutics, medical faculty

119991, Moscow, Pogodinskaya street, 1, bld 1. 

sheptulina.anna@gmail.comШироковаЕ. Н.ShirokovaYe. N.

Широкова Елена Николаевна — доктор медицинских наук, профессор 

Shirokova Yelena N. — MD, PhD, professor

ИвашкинВ. Т.IvashkinV. T.

Ивашкин Владимир Трофимович — академик РАН, доктор медицинских наук, профессор, заведующий кафедрой пропедевтики внутренних болезней 

Ivashkin Vladimir T. — academician of the Russian Academy of Science, MD, PhD, professor, head of the Chair of internal diseases propedeutics, medical faculty

ГБОУ ВПО «Первый Московский государственный медицинский университет им. И. М. Сеченова» Минздрава РоссииРоссияState educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian FederationRussian Federation2015010520152522840Copyright © Шептулина А.Ф., Широкова Е.Н., Ивашкин В.Т., 20152015Шептулина А.Ф., Широкова Е.Н., Ивашкин В.Т.Sheptulina A.F., Shirokova Y.N., Ivashkin V.T.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/1000

Цель обзора. Прогноз и тактика ведения пациентов с хроническими заболеваниями печени любой этиологии во многом определяются степенью развития и протяженностью фиброза, который является своего рода мерой активности, распространенности и длительности существования патологических изменений в печени. Осветить данные вопросы и было целью настоящего сообщения.Основные положения. Благодаря исследованиям в области механизмов фиброгенеза, стала возможной количественная оценка фиброза печени с применением неинвазивных тестов, основанных как на анализе содержания в периферической крови веществ, непосредственно участвующих в различных этапах синтеза и распада внеклеточного матрикса, так и на рутинных лабораторных тестах, отражающих активность воспаления, степень нарушения синтетической функции печени и прогрессирования фиброза.Заключение. Изучение диагностической точности сывороточных маркёров для определения стадии фиброза у пациентов с заболеваниями печени различной этиологии позволит разработать комплексный неинвазивный метод оценки эффективности терапии, характера течения и скорости прогрессирования заболевания.

Aim of review

Aim of review. The prognosis and management approach for chronic liver diseases of any etiology in many respects are determined by stage and extent of fibrosis which reflects activity, spread and duration of liver disease. Aim of current publication was to highlight these issues.

Summary

Summary. Investigations in the field of fibrogenesis processes made possible quantitative estimation of liver fibrosis by non-invasive tests based both on assessment of peripheral blood levels of substances, directly involved in various stages of extracellular matrix synthesis and disintegration, and on the routine laboratory tests reflecting activity of inflammation, degree of disorder of synthetic liver function and fibrosis progression.

Conclusion

Conclusion. Study of diagnostic accuracy of serum markers for assessment of fibrosis stage in liver disea ses of various etiology will provide development of comprehensive non-invasive test for estimation of treatment response rate, course and progression rate of disease

фиброз печенибиопсиянепрямые сывороточные маркёры фиброзапрямые сывороточные маркёры фиброзаliver fibrosisbiopsyindirect serum markers of fibrosisdirect serum markers of fibrosisReferencesБолезни печени и желчевыводящих путей. Руководство для врачей / Под ред. В. Т. Ивашкина. 2-е изд. М.: Изд. Дом «М-Вести», 2005:165 с.Болезни печени и желчевыводящих путей. Руководство для врачей / Под ред. В. Т. Ивашкина. 2-е изд. М.: Изд. Дом «М-Вести», 2005:165 с.Ивашкин В. Т., Павлов Ч. С. Фиброз печени. М.: ГЭОТАР-Медиа, 2011:168 с.Ивашкин В. Т., Павлов Ч. С. Фиброз печени. М.: ГЭОТАР-Медиа, 2011:168 с.Павлов Ч. С. Принципы диагностики и подходы к терапии фиброза и цирроза печени. Рус мед журн 2007; 1:11-6.Павлов Ч. С. Принципы диагностики и подходы к терапии фиброза и цирроза печени. Рус мед журн 2007; 1:11-6.Павлов Ч. С., Ивашкин В. Т., Шульпекова Ю. О., Золотаревский В. Б. Современные представления о патогенезе, диагностике и лечении фиброза печени. Рос журн гастроэнтерол гепатол колопроктол 2005; 15(2):13-20.Павлов Ч. С., Ивашкин В. Т., Шульпекова Ю. О., Золотаревский В. Б. Современные представления о патогенезе, диагностике и лечении фиброза печени. Рос журн гастроэнтерол гепатол колопроктол 2005; 15(2):13-20.Широкова Е. Н. Молекулярные механизмы холестаза. Рос мед вести 2009; 1:15-22.Широкова Е. Н. Молекулярные механизмы холестаза. Рос мед вести 2009; 1:15-22.Alempijevic T., Krstic M., Jesic R. Biochemical markers for non-invasive assessment of disease stage in patients with primary biliary cirrhosis. World J Gastroenterol 2009; 15(5):591-4.Alempijevic T., Krstic M., Jesic R. Biochemical markers for non-invasive assessment of disease stage in patients with primary biliary cirrhosis. World J Gastroenterol 2009; 15(5):591-4.Alkhouri N., McCullough A. J. Noninvasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD. Gastroenterol Hepatol (N Y) 2012; 8(10):661-8.Alkhouri N., McCullough A. J. Noninvasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD. Gastroenterol Hepatol (N Y) 2012; 8(10):661-8.Başar O., Yimaz B., Ekiz F., et al. Non-invasive tests in prediction of liver fibrosis in chronic hepatitis B and comparison with post-antiviral treatment results. Clin Res Hepatol Gastroenterol 2013; 37(2):152-8.Başar O., Yimaz B., Ekiz F., et al. Non-invasive tests in prediction of liver fibrosis in chronic hepatitis B and comparison with post-antiviral treatment results. Clin Res Hepatol Gastroenterol 2013; 37(2):152-8.Berzigottia A., Ashkenazia E., Revertera E., et al. Noninvasive diagnostic and prognostic evaluation of liver cirrhosis and portal hypertension. Dis Markers 2011; 31(3):129-38.Berzigottia A., Ashkenazia E., Revertera E., et al. Noninvasive diagnostic and prognostic evaluation of liver cirrhosis and portal hypertension. Dis Markers 2011; 31(3):129-38.Castera L. Hepatitis B: are non-invasive markers of liver fibrosis reliable? Liver Int 2014; 34(Suppl 1):91-6.Castera L. Hepatitis B: are non-invasive markers of liver fibrosis reliable? Liver Int 2014; 34(Suppl 1):91-6.Castera L. Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. Best Pract Res Clin Gastroenterol 2011; 25(2):291-303.Castera L. Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. Best Pract Res Clin Gastroenterol 2011; 25(2):291-303.Castera L., Pinzani M. Non-invasive assessment of liver fi brosis: are we ready? Lancet 2010; 375(9724):1419-20.Castera L., Pinzani M. Non-invasive assessment of liver fi brosis: are we ready? Lancet 2010; 375(9724):1419-20.Chou R., Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 2013; 158:807-20.Chou R., Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 2013; 158:807-20.Chrostek L., Panasiuk A. Liver fibrosis markers in alcoholic liver disease. World J Gastroenterol 2014; 20(25):8018-23.Chrostek L., Panasiuk A. Liver fibrosis markers in alcoholic liver disease. World J Gastroenterol 2014; 20(25):8018-23.Erdogan S., Dogan H. O., Sezer S., et al. The diagnostic value of non-invasive tests for the evaluation of liver fibrosis in chronic hepatitis B patients. Scand J Clin Lab Invest 2013; 73(4):300-8.Erdogan S., Dogan H. O., Sezer S., et al. The diagnostic value of non-invasive tests for the evaluation of liver fibrosis in chronic hepatitis B patients. Scand J Clin Lab Invest 2013; 73(4):300-8.Farkkila M., Rautiainen H., Karkkainen P., et al. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy. Liver Int 2008; 28(6):787-97.Farkkila M., Rautiainen H., Karkkainen P., et al. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy. Liver Int 2008; 28(6):787-97.Fitzpatrick E., Dhawan A. Noninvasive biomarkers in non-alcoholic fatty liver disease: Current status and a glimpse of the future. World J Gastroenterol 2014; 20(31):10851-63.Fitzpatrick E., Dhawan A. Noninvasive biomarkers in non-alcoholic fatty liver disease: Current status and a glimpse of the future. World J Gastroenterol 2014; 20(31):10851-63.Floreania A., Cazzagona N., Martinesa D., et al. Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis. Dig Liver Dis 2011; 43(11):887-92.Floreania A., Cazzagona N., Martinesa D., et al. Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis. Dig Liver Dis 2011; 43(11):887-92.Friedrich-Rust M., Rosenberg W., Parkes J., et al. Comparison of ELF, FibroTest and FibroScan for the noninvasive assessment of liver fibrosis. BMC Gastroenterol 2010; 10(103):1-8.Friedrich-Rust M., Rosenberg W., Parkes J., et al. Comparison of ELF, FibroTest and FibroScan for the noninvasive assessment of liver fibrosis. BMC Gastroenterol 2010; 10(103):1-8.Garrido M. C., Hubscher S. G. Accuracy of staging in primary biliary cirrhosis. J Clin Pathol 1996; 49:556-9.Garrido M. C., Hubscher S. G. Accuracy of staging in primary biliary cirrhosis. J Clin Pathol 1996; 49:556-9.Gressner A., Gao C., Gressner O. Non-invasive biomarkers for monitoring the fibrogenic process in liver: A short survey. World J Gastroenterol 2009; 15(20):2433-40.Gressner A., Gao C., Gressner O. Non-invasive biomarkers for monitoring the fibrogenic process in liver: A short survey. World J Gastroenterol 2009; 15(20):2433-40.Gümüşay O., Ozenirler S., Atak A., et al. Diagnostic potential of serum direct markers and non-invasive fibrosis models in patients with chronic hepatitis B. Hepatol Res 2013; 43(3):228-37.Gümüşay O., Ozenirler S., Atak A., et al. Diagnostic potential of serum direct markers and non-invasive fibrosis models in patients with chronic hepatitis B. Hepatol Res 2013; 43(3):228-37.Halfon P., Bourlière M., Pénaranda G. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol 2005; 4(6):1-7.Halfon P., Bourlière M., Pénaranda G. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol 2005; 4(6):1-7.Kim B. K., Kim H. S., Yoo E. J., et al. Risk assessment of clinical outcomes in asian patients with chronic hepatitis B using enhanced liver fibrosis test. Hepatology 2014; Accepted article.Kim B. K., Kim H. S., Yoo E. J., et al. Risk assessment of clinical outcomes in asian patients with chronic hepatitis B using enhanced liver fibrosis test. Hepatology 2014; Accepted article.Leroy V., Monier F., Bottari S., et al. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 2004; 99(2):271-9.Leroy V., Monier F., Bottari S., et al. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 2004; 99(2):271-9.Lin Z. H., Xin Y. N., Dong Q. J., et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53:726-36.Lin Z. H., Xin Y. N., Dong Q. J., et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53:726-36.Mahmoud A. A., Bakir A. S., Shabana S. S. Serum TGF-β, Serum MMP-1, and HOMA-IR as non-invasive predictors of fibrosis in Egyptian patients with NAFLD. Saudi J Gastroenterol 2012; 18(5):327-33.Mahmoud A. A., Bakir A. S., Shabana S. S. Serum TGF-β, Serum MMP-1, and HOMA-IR as non-invasive predictors of fibrosis in Egyptian patients with NAFLD. Saudi J Gastroenterol 2012; 18(5):327-33.Mayo M. J., Parkes J., Adams-Huet B., et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis (ELF) assay. Hepatology 2008; 48(5):1549-57.Mayo M. J., Parkes J., Adams-Huet B., et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis (ELF) assay. Hepatology 2008; 48(5):1549-57.McPherson S., Stewart S. F., Henderson E., et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59(9):1265-9.McPherson S., Stewart S. F., Henderson E., et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010; 59(9):1265-9.Montazeri G., Estakhri A., Mohamadnejad M., et al. Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B. BMC Gastroenterol 2005; 5(32):1-7.Montazeri G., Estakhri A., Mohamadnejad M., et al. Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B. BMC Gastroenterol 2005; 5(32):1-7.Nyblom H., Björnsson E., Simrén M., et al. The AST/ ALT ratio as an indicator of cirrhosis in patients with PBC. Liver Int 2006; 26(7):840-5.Nyblom H., Björnsson E., Simrén M., et al. The AST/ ALT ratio as an indicator of cirrhosis in patients with PBC. Liver Int 2006; 26(7):840-5.Pinzani M., Rombouts K., Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 2005; 42:22-36.Pinzani M., Rombouts K., Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 2005; 42:22-36.Poynard T., Munteanu M., Imbert-Bismut F., et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004; 50:1344-55.Poynard T., Munteanu M., Imbert-Bismut F., et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004; 50:1344-55.Rath T., Roderfeld M., Güler C., et al. YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis. Scand J Gastroenterol 2011; 46(11):1369-80.Rath T., Roderfeld M., Güler C., et al. YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis. Scand J Gastroenterol 2011; 46(11):1369-80.Righi S., Fiorini E., De Molo C., et al. ARFI elastography in patients with chronic autoimmune liver diseases: A preliminary study. J Ultrasound 2012; 15(4):226-31.Righi S., Fiorini E., De Molo C., et al. ARFI elastography in patients with chronic autoimmune liver diseases: A preliminary study. J Ultrasound 2012; 15(4):226-31.Rockey Don C., Bissell D. Montgomery. Noninvasive measures of liver fibrosis. Hepatology 2006; 43:113-20.Rockey Don C., Bissell D. Montgomery. Noninvasive measures of liver fibrosis. Hepatology 2006; 43:113-20.Saitou Y., Shiraki K., Yamanaka Y., Yamaguchi Y., Kawakita T., Yamamoto N., Kaszushi S., Murata K., Nakano T. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 2005; 11(4):476-81.Saitou Y., Shiraki K., Yamanaka Y., Yamaguchi Y., Kawakita T., Yamamoto N., Kaszushi S., Murata K., Nakano T. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 2005; 11(4):476-81.Schiavon L., Narciso-Schiavon J., de CarvalhoFilho R. J. Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. World J Gastroenterol 2014; 20(11):2854-66.Schiavon L., Narciso-Schiavon J., de CarvalhoFilho R. J. Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. World J Gastroenterol 2014; 20(11):2854-66.Sowa J. P., Atmaca Ö., Kahraman A. Non-invasive separation of alcoholic and non-alcoholic liver disease with predictive modeling. PLoS One 2014; 9(7).Sowa J. P., Atmaca Ö., Kahraman A. Non-invasive separation of alcoholic and non-alcoholic liver disease with predictive modeling. PLoS One 2014; 9(7).Suzuki A., Angulo P., Lymp J., et al. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2005; 25:779-86.Suzuki A., Angulo P., Lymp J., et al. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2005; 25:779-86.Trivedi P. J., Bruns1 T., Cheung A., et al. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. J Hepatol 2014; 60(6):1249-58.Trivedi P. J., Bruns1 T., Cheung A., et al. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. J Hepatol 2014; 60(6):1249-58.Voumvouraki A., Koulentaki M., Notas G., et al. Serum surrogate markers of liver fibrosis in primary biliary cirrhosis. Eur J Intern Med 2011; 22(1):77-83.Voumvouraki A., Koulentaki M., Notas G., et al. Serum surrogate markers of liver fibrosis in primary biliary cirrhosis. Eur J Intern Med 2011; 22(1):77-83.

The authors declare that there are no conflicts of interest present.